Mindmed collaborators announce positive topline data from phase 2 trial of lysergide (lsd) in major depressive disorder (mdd)

New york--(business wire)---- $mnmd--mind medicine (mindmed) inc (nasdaq: mnmd), (neo: mmed), (the “company” or “mindmed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that prof. matthias liechti and dr.
MNMD Ratings Summary
MNMD Quant Ranking